Trials / Completed
CompletedNCT00885989
Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers
A Placebo-Controlled, Combined Single and Multiple Rising Dose Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV338 After Intravenous Administration in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate the safety and tolerability of the first IV dosing of SLV338 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SLV338 | 5 - 1000 mg IV |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2009-04-22
- Last updated
- 2010-01-29
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00885989. Inclusion in this directory is not an endorsement.